The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2015

Filed:

Aug. 31, 2010
Applicants:

Solomon Langermann, Baltimore, MD (US);

Linda Liu, Clarksville, MD (US);

Joseph R. Podojil, Downers Grove, IL (US);

Stephen D. Miller, Oak Park, IL (US);

Shannon Marshall, Baltimore, MD (US);

Inventors:

Solomon Langermann, Baltimore, MD (US);

Linda Liu, Clarksville, MD (US);

Joseph R. Podojil, Downers Grove, IL (US);

Stephen D. Miller, Oak Park, IL (US);

Shannon Marshall, Baltimore, MD (US);

Assignee:

Amplimmune, Inc., Gaithersburg, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/16 (2006.01); C07K 14/705 (2006.01); C07K 16/46 (2006.01); G01N 33/68 (2006.01); A61K 38/17 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6863 (2013.01); A61K 38/1709 (2013.01); C07K 14/70532 (2013.01); C07K 16/2827 (2013.01); C07K 2317/50 (2013.01); C07K 2317/56 (2013.01); C07K 2317/72 (2013.01); C07K 2319/32 (2013.01); G01N 33/6866 (2013.01); G01N 33/6869 (2013.01); G01N 2800/52 (2013.01);
Abstract

Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.


Find Patent Forward Citations

Loading…